Page last updated: 2024-11-04

pindolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pindolol is a non-selective beta blocker with partial agonist activity at beta-adrenergic receptors. It was first synthesized in the 1960s and has been used clinically for the treatment of hypertension, angina, and migraine. It is also used in research to study the role of beta-adrenergic receptors in various physiological processes. Pindolol is thought to exert its effects by blocking the binding of norepinephrine and epinephrine to beta-adrenergic receptors, which reduces the activation of adenylyl cyclase and the production of cyclic AMP. This leads to a decrease in heart rate, blood pressure, and myocardial contractility. Pindolol is also a serotonin antagonist, which may contribute to its effects on migraine and anxiety. It is important to note that pindolol is a non-selective beta blocker, meaning that it blocks both beta1 and beta2 receptors. This can lead to unwanted side effects, such as bronchospasm, in individuals with asthma or other respiratory conditions. Pindolol is generally well-tolerated, but it can cause side effects such as dizziness, fatigue, and nausea. It is important to consult with a healthcare professional before taking pindolol.'

Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4828
CHEMBL ID500
CHEBI ID8214
SCHEMBL ID5219
MeSH IDM0016872

Synonyms (220)

Synonym
HMS3267K17
BRD-A97701745-001-05-3
gtpl91
DIVK1C_000837
KBIO1_000837
1-(1h-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol
blocklin
blocklin-l
EU-0100955
pindolol, >=98% (tlc), powder
SPECTRUM_001109
PDSP1_000772
LOPAC0_000955
pindololum [inn-latin]
2-propanol, 1-(1h-indol-4-yloxy)-3-(1-methylethyl)amino-
ccris 9215
1-(1h-indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol
2-propanol, 1-(4-indolyloxy)-3-(isopropylamino)-
2-propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)-
2-propanol, 1-(1h-indol-4-yloxy)-3-((1-methylethyl)amino)-
einecs 244-623-8
4-(3-(isopropylamino)-2-hydroxypropoxy)indole
prindolol
lb-46
hsdb 6539
glauco-viskin
1-(indol-4-yloxy)-3-(isopropylamino)-2-propanol
(+-)-pindolol
1-((1-methylethyl)amino)-3-(4-indolyloxy)-2-propanol
brn 1536506
(1)-1-(1h-indol-4-yloxy)-3-(isopropylamino)propan-2-ol
einecs 236-867-9
PRESTWICK_397
PRESTWICK2_000090
PDSP1_000771
BSPBIO_002193
SPECTRUM5_001266
BPBIO1_000022
PRESTWICK3_000090
IDI1_000837
visken
1-(1h-indol-4-yloxy)-3-(isopropylamino)propan-2-ol
prinodolol
dl-4-[2-hydroxy-3-(isopropylamino)propoxy]indole
dl-lb 46
dl-pindolol
2-propanol, 1-(1h-indol-4-yloxy)-3-[(1-methylethyl)amino]-
lb 46
carvisken
AB00052072
pindolol
C07445
13523-86-9
4-(2-hydroxy-3-isopropylaminopropoxy)-indole
1-(1h-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol
DB00960
blocklin-l (tn)
carvisken (tn)
pindolol (jp17/usp/inn)
D00513
visken (tn)
NCGC00024925-04
NCGC00024925-05
NCGC00024925-07
MLS000069496
smr000059120
KBIOGR_000958
KBIO2_001589
KBIO2_004157
KBIO3_001693
KBIO2_006725
KBIOSS_001589
SPBIO_001289
SPECTRUM2_001285
PRESTWICK1_000090
NINDS_000837
SPECTRUM4_000479
PRESTWICK0_000090
SPBIO_001959
SPECTRUM3_000547
SPECTRUM1500488
OPREA1_770884
BSPBIO_000020
PDSP2_000759
PDSP2_000760
NCGC00024925-06
NCGC00024925-03
glauco-visken
blocklin l
betapindol
durapindol
pectobloc
pynastin
decreten
blockin l
pindololum
1-(1h-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
CHEBI:8214 ,
pinbetol
calvisken
P-6820 ,
NCGC00015786-07
P 0778 ,
HMS2091P20
HMS2089I21
NCGC00015786-13
L000006
apo-pindol
(rs)-pindolol
nsc-757276
dl-lb-46
CHEMBL500
HMS502J19
HMS1920H16
HMS1568A22
1-(1h-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-(1h-indol-4-yloxy)-3-isopropylamino-propan-2-ol((-)-pindolol)
pindolol,(-)
1-(1h-indol-4-yloxy)-3-isopropylamino-propan-2-ol
bdbm50019443
1-(1h-indol-4-yloxy)-3-isopropylamino-propan-2-ol(pindolol)
NCGC00015786-11
HMS3262P12
HMS3259I07
HMS2095A22
nsc757276
MLS002548891
pharmakon1600-01500488
dtxsid8023476 ,
dtxcid603476
tox21_110221
AKOS015969756
CCG-39223
NCGC00015786-10
NCGC00015786-09
NCGC00015786-08
NCGC00015786-06
NCGC00015786-14
nsc 757276
pindolol [usan:usp:inn:ban:jan]
unii-bj4hf6iu1d
bj4hf6iu1d ,
5-21-03-00017 (beilstein handbook reference)
1-(1h-indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol
FT-0673907
LP00955
HMS3369E14
4-(3-isopropylamino-2-hydroxypropoxy)indole
dl-4-(2-hydroxy-3-(isopropylamino)propoxy)indole
4-(2-hydroxy-3-isopropylaminopropoxy)indole
n-(2-hydroxy-3-(1h-indol-4-yloxy)propyl)-n-isopropylamine
pindolol [ep monograph]
pindolol [usan]
pindolol [usp monograph]
pindolol component of viskazide
pindolol [hsdb]
(+/-)-pindolol
pindolol [mi]
pindolol [usp-rs]
(+/-)-4-(2-hydroxy-3-(isopropylamino)propoxy)indole
pindolol [orange book]
viskazide component pindolol
pindolol [vandf]
pindolol [inn]
(+/-)-lb-46
pindolol [jan]
2-propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-
pindolol [mart.]
pindolol [who-dd]
NC00467
SCHEMBL5219
NCGC00015786-16
tox21_110221_1
AB00052072-11
tox21_500955
CS-4473
NCGC00261640-01
1-(1h-indol-4-yloxy)-3-(isopropylamino)-2-propanol #
(.+/-.)-pindolol
1-(4-indolyloxy)-3-(isopropylamino)-2-propanol
1-((1h-indol-4-yl)oxy)-3-(isopropylamino)propan-2-ol
HY-B0982
AB00052072_13
AB00052072_12
SR-01000000027-2
sr-01000000027
pindolol, united states pharmacopeia (usp) reference standard
C90604
pindolol, european pharmacopoeia (ep) reference standard
SR-01000000027-5
SR-01000000027-7
SR-01000000027-4
SBI-0050929.P004
NCGC00015786-20
HMS3712A22
SW196641-3
Q418101
HMS3678H21
HMS3414J03
BRD-A97701745-001-09-5
SB17015
SDCCGSBI-0050929.P005
NCGC00015786-22
HMS3885N04
HMS3742C07
(-)-pindolol; (s)-(-)-pindolol; s-pindolol
BS-42390
EN300-18518413
pindolol (usp-rs)
c07aa03
(2rs)-1-(1h-indol-4-yloxy)-3-(1-methylethyl)aminopropan-2-ol
pindolol (mart.)
pindolol (ep monograph)
pindolol (usp monograph)
pindolol (usan:usp:inn:ban:jan)
pindololum (inn-latin)
1-(1h-indol-4-yloxy)-3-((1-methylethyl)amino)propan-2-ol
1-(1h-indol-4-yloxy)-3-((propan-2-yl)amino)propan-2-ol
1-(1h-indol-4-yloxy)-3-)(1-methylethyl)amino)-2-propanol
pindololo

Research Excerpts

Overview

Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) for the treatment of cardiovascular diseases such as hypertension and angina pectoris. It is an indolic drug that has been shown to enhance and/or accelerate selective serotonin specific reuptake inhibitors (SSRI) effect.

ExcerptReferenceRelevance
"Pindolol (PDL) is a potent and specific adrenoreceptor blocking agent. "( Rational synthesis of pindolol imprinted polymer by non-covalent protocol based on computational approach.
Motghare, RV; Tadi, KK, 2013
)
2.15
"Pindolol is a beta-blocker used to treat cardiovascular disorders."( Intermolecular complexation of low-molecular-weight succinoglycans directs solubility enhancement of pindolol.
Cho, E; Choi, JM; Choi, Y; Jang, A; Jung, S; Kim, H; Kim, K; Lee, IS; Yu, JH, 2014
)
1.34
"Pindolol is a representative of this type of compound, either from the structural point of view, or as reference for comparison of the pharmacokinetic properties of the beta-blockers."( A study of the structure of the pindolol based on infrared spectroscopy and natural bond orbital theory.
Canotilho, J; Castro, RA; Eusébio, ME; Nunes, SC; Redinha, JS, 2009
)
1.36
"Pindolol is an indolic drug that has been shown to enhance and/or accelerate selective serotonin specific reuptake inhibitors (SSRI)-induced antidepressant (AD) effect, even though the respective mechanism is still unclear. "( Pindolol is a potent scavenger of reactive nitrogen species.
Costa, D; Fernandes, E; Gomes, A; Lima, JL, 2005
)
3.21
"Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) for the treatment of cardiovascular diseases such as hypertension and angina pectoris. "( Enantiomeric separation and quantification of pindolol in human plasma by chiral liquid chromatography/tandem mass spectrometry using staggered injection with a CTC Trio Valve system.
Shen, Z; Wang, H, 2006
)
2.03
"Pindolol is a beta-adrenoceptor-blocking drug with partial agonist activity (intrinsic sympathomimetic activity [ISA])."( Clinical pharmacology of pindolol.
Aellig, WH, 1982
)
1.29
"1 Pindolol is a beta-adrenoceptor antagonist equally effective on beta 1- and beta 2-adrenoceptors which has a relatively long duration of action. "( Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.
Aellig, WH, 1982
)
2.43
"Pindolol is a new noncardioselective beta adrenergic blocking agent with intrinsic sympathomimetic activity. "( Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.
Golightly, LK,
)
3.02
"Pindolol is a drug with sufficient ISA to compensate for blockade of sympathetic drive at rest."( Clinical pharmacology of beta-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol.
Aellig, WH, 1983
)
1.2
"Pindolol is a non-selective beta-adrenoceptor blocking agent with relatively marked intrinsic sympathomimetic activity. "( Effects of pindolol on vascular smooth muscle.
Bertholet, A; Clark, BJ, 1983
)
2.1
"1 Pindolol is a non-selective beta-adrenoceptor blocking agent; its affinity to adrenoceptors in guinea pig atria (beta 1) is not significantly different from that in guinea pig trachea (beta 1 + beta 2) and canine vascular smooth muscle (beta 2). "( Pindolol--the pharmacology of a partial agonist.
Bertholet, A; Clark, BJ; Menninger, K, 1982
)
2.43
"Pindolol is a non-selective beta-adrenoceptor partial agonist, whereas xamoterol is beta 1-selective and possesses a higher degree of agonist activity."( Differential effects of beta-adrenoceptor partial agonists in patients with postural hypotension.
Mehlsen, J; Stadeager, C; Trap-Jensen, J, 1993
)
1.01
"Cyanopindolol (CYP) is a potent antagonist at the beta 3-adrenoceptor in rat ileum."( Characteristics of cyanopindolol analogues active at the beta 3-adrenoceptor in rat ileum.
Hoey, AJ; Jackson, CM; Pegg, GG; Sillence, MN, 1996
)
1.06
"Pindolol is an antagonist of both serotonin autoreceptors and beta-adrenoceptors."( Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
Alvarez, E; Artigas, F; Faries, D; Gilaberte, I; Pérez, V, 1997
)
1.27
"Pindolol proved to be an effective treatment, even in patients who had previously failed treatment with conventional beta blockers, suggesting a clinical benefit from addition of ISA to beta blockade in this setting."( Usefulness of pindolol in neurocardiogenic syncope.
Dutton, J; Iskos, D; Lurie, KG; Scheinman, MM, 1998
)
1.38
"(+/-)Pindolol is a beta-adrenergic/5-HT1A receptor antagonist used in combination with certain antidepressant drugs to accelerate the onset of the antidepressive response."( Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol.
Blier, P; de Montigny, C; Haddjeri, N, 1999
)
1.04
"Pindolol is an beta-adrenoreceptor antagonist with a high affinity to 5-HT(1A) receptors."( Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development.
Andrée, B; Farde, L; Halldin, C; Sandell, J; Thorberg, SO, 2000
)
1.03
"Pindolol (Viskén) is a beta-adrenoceptor blocking agent with intrinsic sympathomimetic effect and is characterized by high potency and long duration."( Long-term blood pressure control with pindolol given once daily.
Danielson, M; Frithz, G; Henningsen, N; Malmborg, RO; Nordström-Ohrberg, G; Schröder, G,
)
1.12
"Pindolol was shown to be a safe, effective and well tolerated hypotensive agent."( The use of pindolol in the treatment of essential hypertension: a multi-centre assessment.
Blowers, AJ; Melvin, MA, 1976
)
1.37
"Bopindolol is a nonselective beta blocker with mild intrinsic sympathomimetic activity. "( Bopindolol: Czechoslovak experience with a new beta blocker in the treatment of hypertension.
Dvorák, I; Fedelesová, V; Lefflerová, K; Lupínek, Z; Mayer, O; Pinterová, E; Widimský, J, 1991
)
1.72
"Bopindolol is a nonselective beta-adrenoceptor antagonist [corrected] with partial agonist activity which is used in the treatment of hypertension. "( Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Goa, KL; Harron, DW; Langtry, HD, 1991
)
1.72
"Mepindolol is a newly developed beta-adrenergic blocking agent reported to counteract the chronotropic effect of catecholamines, with only little effect on contractility. "( Mepindolol reduces myocardial necrosis in rats with coronary artery occlusion.
Ambrosio, G; Cappelli-Bigazzi, M; Chiariello, M; Condorelli, M; Marone, G; Perrone-Filardi, P; Tritto, I,
)
1.57
"Bopindolol is a potent beta-adrenoceptor antagonist with mild intrinsic sympathomimetic activity that exhibits a long duration of action. "( Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
Aellig, WH, 1986
)
1.21
"Bopindolol is a new beta blocker with a long duration of action which exerts antihypertensive effects at very low dosage. "( Dose-finding study with bopindolol in arterial hypertension.
Peter, R; Siegenthaler, H; Willimann, P, 1986
)
1.29
"Bopindolol is a new beta blocker with a long duration of action. "( Effects of bopindolol on left ventricular function during exercise in patients with coronary artery disease.
Mérier, G; Ratib, O; Righetti, A; Rutishauser, W; Viquerat, C, 1986
)
1.36
"Bopindolol is a new beta blocker with a long duration of action and antihypertensive properties at low dosage."( Antihypertensive treatment with bopindolol alone or combined with a diuretic in general practice.
Bousquet, JC; Weidmann, P, 1986
)
1.11
"Mepindolol is a newly developed beta-adrenergic blocking agent, which differs from other available beta-blockers in its ability to counteract the chronotropic effect of catecholamines without depressing myocardial contractility. "( [Mepindolol reduction of the degradation of phospholipids and the necrosis induced by myocardial ischemia].
Ambrosio, G; Cappelli Bigazzi, M; Chiariello, M; Pellegrino, A; Perrone Filardi, P; Vallone, C, 1985
)
1.61
"Bopindolol is a potent and specific beta-adrenoceptor antagonist with partial agonist activity. "( Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.
Aellig, WH, 1985
)
1.24
"Bopindolol is a new long-acting, nonselective beta-adrenoceptor antagonist with partial agonist activity. "( The clinical pharmacology of bopindolol, a new long-acting beta-adrenoceptor antagonist, in hypertension.
Boomsma, F; Derkx, FH; Man in 't Veld, AJ; Mulder, P; Schalekamp, MA; van den Meiracker, AH; van Eck, HJ, 1987
)
1.28
"1. Pindolol is a beta-adrenoceptor blocking drug with ISA (also called partial agonist activity). "( Is the ISA of pindolol beta 2-adrenoceptor selective?
Aellig, WH; Clark, BJ, 1987
)
1.25

Effects

Bopindolol has beta-blocking effects for 96 hr despite a 4-hr t1/2. Small doses reduce femoral and mesenteric vascular resistance by approximately 30%. Pindoll has been reported to block the effects of buspirone but not chlordiazepoxide.

ExcerptReferenceRelevance
"Pindolol has a strong both positive chronotropic and inotropic efficacy, even at small therapeutic doses."( Sympathomimetic and cardiodepressant effects of acebutolol, oxprenolol, pindolol, and propranolol. A comparative study on changes in hemodynamics, contractility, heart rate, and AV-conduction time at therapeutic doses.
Bender, F; Gülker, H; Heuer, H; Kristek, J, 1981
)
1.22
"Pindolol has the potential to prevent the inhibition of serotonergic neurons after antidepressant use. "( Pindolol potentiates the antidepressant effect of venlafaxine by inhibiting 5-HT1A receptor in DRN neurons of mice.
Bal, R; Yaman, B, 2022
)
3.61
"Pindolol has been widely investigated as an augmenter of antidepressant drug response. "( A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
Bech, P; Lunde, M; Martiny, K; Plenge, P, 2012
)
2.05
"Pindolol has a strong both positive chronotropic and inotropic efficacy, even at small therapeutic doses."( Sympathomimetic and cardiodepressant effects of acebutolol, oxprenolol, pindolol, and propranolol. A comparative study on changes in hemodynamics, contractility, heart rate, and AV-conduction time at therapeutic doses.
Bender, F; Gülker, H; Heuer, H; Kristek, J, 1981
)
1.22
"Bopindolol has beta-blocking effects for 96 hr despite a 4-hr t1/2. "( Simultaneous modeling of bopindolol kinetics and dynamics.
Galeazzi, RL; Niederberger, W; Platzer, R; Rosenthaler, J, 1984
)
1.29
"Pindolol has been used in internal medicine for more than 12 years now."( [Clinical suitability of pindolol eyedrops in the treatment of chronic open-angle glaucoma].
Dausch, D; Görlich, W; Honegger, H, 1984
)
1.29
"5 Pindolol has marked vasodilator activity, small doses reducing femoral and mesenteric vascular resistance by approximately 30%."( Pindolol--the pharmacology of a partial agonist.
Bertholet, A; Clark, BJ; Menninger, K, 1982
)
2.27
"Pindolol has been reported to block the effects of buspirone but not chlordiazepoxide."( The interaction of serotonin depletion with anxiolytics and antidepressants on reticular-elicited hippocampal RSA.
McNaughton, N; Zhu, XO, 1994
)
1.01
"Pindolol has been shown to be a partial agonist at 5-HT1A receptors in preclinical studies. "( Effect of pindolol on hormone secretion and body temperature: partial agonist effects.
Maes, M; Meltzer, HY, 1996
)
2.14
"Pindolol has been reported to hasten the antidepressant action of selective serotonin reuptake inhibitors in open-label and placebo-controlled trials. "( A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Alvarez, E; Artigas, F; Pérez, V; Puigdemont, D; Soler, J, 1999
)
1.99
"Pindolol has been reported to shorten the onset of antidepressant action of selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) as well as to increase their efficacy. "( Partial 5-HT1A receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo.
Ahlenius, S; Arborelius, L; Linnér, L; Svensson, TH; Wallsten, C, 2000
)
2

Actions

Pindolol may produce this effect, which was not seen with xamoterol, because of its specific beta 2-adrenoceptor partial agonist activity. Pindlol tended to cause least change from placebo in resting spirometry, caused significant tremor response, inhibited the fenoterol airway response, and tended to protect against inhaled histamine.

ExcerptReferenceRelevance
"5 Pindolol tended to cause least change from placebo in resting spirometry, caused significant tremor response, inhibited the fenoterol airway response, and tended to protect against inhaled histamine."( Assessment of beta-adrenoceptor antagonists in asthmatic patients.
Alpers, JH; Crockett, AJ; Latimer, KM; McIntyre, EL; Ruffin, RE; Ward, HE, 1982
)
0.82
"2 Pindolol displays a striking diversity of agonist activities in isolated tissues."( Pindolol--the pharmacology of a partial agonist.
Bertholet, A; Clark, BJ; Menninger, K, 1982
)
2.27
"Pindolol do not lower PRA in normotensive rats but increases levels of PRA in spontaneously hypertensive rats."( [Action of 3-beta adrenolytics on plasma renin activity measured by radioimmunology in genetically hypertensive rats].
Lacroix, P; Le Pollés, JB; Linée, P; Pape, D; Van den Driessche, J, 1977
)
0.98
"pindolol to produce maximum cardiac beta-adrenoceptor blockade there were differences in inhibition of resting heart rate, slope, HR50 and maximum heart rate suggesting differences in sympathetic components."( Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia.
Bobik, A; Fagan, ET; Jennings, GL; Korner, PI, 1979
)
2.42
"6. Pindolol may produce this effect, which was not seen with xamoterol, because of its specific beta 2-adrenoceptor partial agonist activity."( Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.
Cruickshank, JM; Graham, BR; Hayes, Y; Jones, A; Lewis, AD; Lui, JB; Prichard, BN; Renondin, JC; Tomlinson, B, 1990
)
1.04
"The pindolol-induced increase in FBF was reduced by concomitant infusion of propranolol (p less than 0.001)."( Acute vasodilator action of pindolol in humans.
Chang, PC; van Brummelen, P; Vermeij, P,
)
0.91

Treatment

Pindolol treatment allowed the serotonergic and non-serotonergic components of prolactin release to be distinguished. The drug was associated with a higher incidence of paraesthesias and more intense nightmares and hallucinations than MPH or placebo treatment.

ExcerptReferenceRelevance
"Pindolol treatment allowed the serotonergic and non-serotonergic components of prolactin release to be distinguished."( Responses to exercise in the heat related to measures of hypothalamic serotonergic and dopaminergic function.
Bridge, MW; Jones, DA; Rayson, M; Weller, AS, 2003
)
1.04
"Pindolol treatment reduced serum calcium concentration."( Renal function, body fluid volumes, renin, aldosterone, and noradrenaline during treatment of hypertension with pindolol.
Bluhm, MM; Lancaster, R; Lewis, PS; Osikowska, BA; Peart, WS; Sever, PS; Suddle, SA; Veall, N; Wilcox, CS,
)
1.06
"Pindolol pretreatment decreases the severity of ARF though it can not prevent it."( Effect of the beta-receptor blocker pindolol on survival in HgCl2 induced acute renal failure in dogs.
Gaál, K; Siklós, J, 1981
)
1.26
"With pindolol, treatment exercise tolerance was increased 13% (33 seconds) over baseline levels but only 2% over the levels achieved with placebo treatment (not significant)."( Randomized double-blind study of pindolol in patients with stable angina pectoris.
Friesinger, GC; Harston, WE, 1982
)
1
"Pindolol pretreatment lowered baseline PRL levels but, when this effect was taken into account, did not significantly attenuate the PRL response to d-FEN."( Effect of pindolol on the prolactin response to d-fenfluramine.
Cowen, PJ; Park, SB, 1995
)
1.41
"Pindolol pretreatment attenuated the (+)-fenfluramine-induced increase in prolactin concentrations but failed to affect the (+)-fenfluramine-induced cortisol increase."( Evidence for 5-hydroxytryptamine1A receptor involvement in the control of prolactin secretion in man.
Butler, J; Chambers, S; Coskeran, P; McGregor, AM; Palazidou, E; Stephenson, J, 1995
)
1.01
"Pindolol treatment was associated with a higher incidence of paraesthesias and with more intense nightmares and hallucinations than MPH or placebo treatment."( Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects.
Buitelaar, JK; Kuiper, M; Swaab-Barneveld, H; van der Gaag, RJ, 1996
)
2.46
"Pindolol treatment was associated with statistically significant reduction in blood pressure and pulse as compared to the control group."( The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial.
Anand, A; Berman, RM; Cappiello, A; Charney, DS; Hu, XS; Miller, HL; Oren, DA, 1999
)
1.41
"Pindolol pre-treatment also, on average, delayed the onset and peak of the prolactin response."( Quantifying the 5-HT1A agonist action of buspirone in man.
Bridge, MW; Jones, DA; Kendall, MJ; Marvin, G; Sharma, A; Thompson, CE, 2001
)
1.03
"The pindolol treatment caused a significant decrease in the systemic systolic and diastolic blood pressure, both at rest and during work."( Experience with pindolol, a betareceptor blocker, in the treatment of hypertension.
Atterhög, JH; Dunér, H; Pernow, B, 1976
)
1.08
"The pindolol treatment lead a significant decrease in the systolic and diastolic blood pressure, at rest and during work both after 2 months and after 16 months treatment."( Haemodynamic effects of pindolol in hypertensive patients.
Atterhög, JH; Dunér, H; Pernow, B, 1977
)
1.04
"The pindolol treatment caused a significant decrease in the systemic systolic and diastolic blood pressure, heart rate and cardiac output both at rest and during work."( Hemodynamic effect of pindolol in essential hypertension with special reference to the resistance and capacitance vessels of the forearm.
Atterhög, JH; Dunér, H; Pernow, B, 1976
)
1.05
"Mepindolol treatment decreased beta 2-adrenoceptor density from 1112.2 +/- 459.6 sites/cell to 295.1 +/- 131.2 sites/cell."( [Activity and number of lymphocyte beta adrenergic receptors after protracted treatment with mepindolol sulfate of patients with essential arterial hypertension].
Carretta, R; Castellano, M; De Biasi, F; Fabris, B; Fischetti, F; Leprini, R, 1990
)
1.06
"The pindolol-treated and propranolol-treated rats gained weight during the cold-acclimatization period."( Influence of two beta-adrenoceptor antagonists, propranolol and pindolol, on cold adaptation in the rat.
Huttunen, P; Kortelainen, ML; Lapinlampi, T, 1990
)
1
"Pindolol treatment increased resting values of HDL cholesterol (from 43 +/- 4 to 48 +/- 4 mg/dl) and potentiated the response to exercise (to 59 +/- 5 vs."( Beta-blockade with intrinsic sympathetic activity modifies favorably exercise-induced changes in plasma lipoproteins.
Cleroux, J; Leenen, FH; Peterson, M; Van Nguyen, P, 1990
)
1
"Pindolol pretreatment (40 mg over 48 h) markedly attenuated the GH response to LTP and modestly, but significantly, reduced the LTP-induced increase in plasma PRL."( Pindolol decreases prolactin and growth hormone responses to intravenous L-tryptophan.
Cowen, PJ; Smith, CE; Ware, CJ, 1991
)
2.45
"Pindolol treatment was associated with a 25% increase in total beta-adrenoceptor density (72.3 vs."( Effects of chronic pindolol treatment on human myocardial beta 1- and beta 2-adrenoceptor function.
Bjørnerheim, R; Golf, S; Hansson, V, 1990
)
1.33
"Pindolol treatment (2 X 5 mg/day) caused a 50% decrease of beta 2-adrenoceptor density after 2 days, which remained reduced during treatment."( Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.
Brodde, OE; Daul, A; O'Hara, N; Schiess, W; Wang, XL, 1986
)
1.27
"Pindolol, reserpine-pretreatment or tetrodotoxin did not modify the PIE of MCI-154."( Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP?
Endoh, M; Kitada, Y; Narimatsu, A; Suzuki, R; Taira, N, 1987
)
0.99
"Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment."( Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".
Borchard, U; Brodde, OE; Daul, A; O'Hara, N; Stuka, N, 1985
)
0.83
"Mepindolol-treated rats, however, showed a phospholipid concentration of 0.70 +/- 0.04 microgram P/mg of protein (p less than 0.05), suggesting that the drug was able to prevent ischemia-induced phospholipase activation.(ABSTRACT TRUNCATED AT 250 WORDS)"( [Mepindolol reduction of the degradation of phospholipids and the necrosis induced by myocardial ischemia].
Ambrosio, G; Cappelli Bigazzi, M; Chiariello, M; Pellegrino, A; Perrone Filardi, P; Vallone, C, 1985
)
1.45
"Pindolol treatment was associated with significant therapeutic benefits without sedation and without the use-limiting side effects that occur with propranolol."( Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study.
Greendyke, RM; Kanter, DR, 1986
)
1.3
"Pindolol treatment resulted in almost total inhibition of the increase in plasma TxB2 and AA during exercise."( The effect of pindolol on exercise-induced increase in plasma vasoactive prostanoids and catecholamines in healthy men.
Laustiola, K; Salo, M; Seppälä, E; Uusitalo, A; Vapaatalo, H; Vuorinen, P, 1985
)
1.35
"Pretreatment with pindolol, 30 mg orally, significantly inhibited the PRL but not the cortisol response to L-5-HTP, 200 mg PO."( Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.
Maes, M; Meltzer, HY, 1994
)
1.01
"Pretreatment with pindolol, a 5-HT-1A antagonist, reduced the hypothermic response to 8-OH-DPAT, but pretreatment with ritanserin, a 5-HT-7 and 5-HT-2A/C antagonist, had no effect, confirming that the hypothermic response to 8-OH-DPAT is mediated predominantly by 5-HT-1A receptors."( Further selection of rat lines differing in 5-HT-1A receptor sensitivity: behavioral and functional correlates.
Crews, FT; Janowsky, DS; Knapp, DJ; Overstreet, DH; Rezvani, AH, 1996
)
0.62

Toxicity

Chronotoxicity of a single LD50 dosage of beta-adrenoceptor blocking agent, pindolol, was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto control rats (WKY) The order of the fed:fasted ratio of LD50 values in rats was pirenzepin less than propantheline.

ExcerptReferenceRelevance
" Chronotoxicity of a single LD50 dosage of beta-adrenoceptor blocking agent, pindolol, was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto control rats (WKY)."( Chronotoxicity of beta-adrenoceptor blocking agent in spontaneously hypertensive rats.
Ebihara, A; Fujimura, A, 1987
)
0.5
" All adverse events reported in connection with administration of pindolol have been carefully analyzed since this drug was marketed 10 years ago."( Pindolol: experience gained in 10 years of safety monitoring.
Fanchamps, A; Krupp, P, 1982
)
1.94
" The side-effect score for edema was lower with ISR plus diuretics than with other combinations, whereas the ACE inhibitor was associated with a higher score for cough."( Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial.
Lüscher, TF; Waeber, B, 1993
)
0.29
" Since beta-blockers cross the placenta, it is essential to consider possible adverse effects on the embryo."( Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.
Klug, S; Merker, HJ; Neubert, D; Schwabe, R; Thiel, R, 1994
)
0.29
" Using drugs together may increase the risk of adverse effects, through potentiation of existing adverse effects or alterations in plasma concentrations of the drug."( Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.
Schweitzer, I; Tuckwell, V, 1998
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Chronic hypertension is associated with adverse perinatal outcomes, although the optimal treatment is unclear."( Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020
)
0.56

Pharmacokinetics

The pharmacodynamic effects of acute and repeated application of a transdermal patch (BIO TSD) containing 20 mg of the beta-receptor blocking agent mepindolol were assessed in 13 normotensive male volunteers. The goal of the present work was to determine the effect of clarithromycin (CAM) administration on the pharmacokinetic properties of pindlol in rats.

ExcerptReferenceRelevance
" The estimated pharmacokinetic parameters do not differ significantly in Africans from the values which have been obtained in other races."( Pharmacokinetics of pindolol in Africans.
Adio, RA; Falase, AO; Ragon, A; Salako, LA, 1979
)
0.58
" The plasma elimination half-life was identical after SD (4."( Single and multiple dose pharmacokinetics of pindolol.
Bodem, G; Gugler, R, 1978
)
0.52
" Compared to patients with normal renal function, patients with chronic renal failure exhibited (i) unchanged K12 and K21 and nonrenal clearances, and (ii) significantly decreased values in half-life of the beta phase, Kel, and total renal clearance."( Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
Agorus, N; Georges, D; Lavene, D; Loria, Y; Milliez, PL; Safar, ME; Weiss, YA,
)
0.39
" application by using a simple pharmacokinetic model was tested."( Percutaneous absorption of pindolol and pharmacokinetic analysis of the plasma concentration.
Iwaki, M; Ogiso, T; Oue, H; Tanino, T, 1992
)
0.58
" In two separate studies, each with 12 healthy male volunteers, the pharmacokinetic and dynamic properties of a transdermal delivery system for bopindolol were evaluated."( Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
Drewe, J; Gyr, K; Kissel, T; Meier, R; Munzer, J; Thumshirn, M; Timonen, U, 1991
)
0.71
"Steady-state pharmacokinetic parameters of the new, long-acting beta-adrenoceptor blocker bopindolol have been measured in 17 young and 20 elderly healthy men."( Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.
Holmes, D; Houle, JM; Nuesch, E; Rosenthaler, J, 1991
)
0.76
" In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h)."( Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
Grevel, J, 1986
)
0.49
"The pharmacodynamic effects of acute and repeated application of a transdermal patch (BIO TSD) containing 20 mg of the beta-receptor blocking agent mepindolol were assessed in 13 normotensive male volunteers."( [Human pharmacologic studies on transdermal administration of mepindolol. Pharmacodynamic and orienting pharmacokinetics].
Chen, LS; Haase, W; Liedtke, RK; Mangold, B, 1989
)
0.71
" The pharmacokinetic absorption behavior of a sustained-release preparation of diltiazem hydrochloride was studied using a multi-fraction absorption model."( Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models.
Kohno, K; Murata, K; Noda, K; Samejima, M, 1987
)
0.27
" Renal clearance and other pharmacokinetic parameters of both enantiomers were calculated and compared."( Stereoselective renal clearance of pindolol in humans.
Giacomini, KM; Hsyu, PH, 1985
)
0.55
" Synchronously with pharmacodynamics, pharmacokinetic data were also obtained after multiple dosing."( Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
Bonelli, J; Hitzenberger, G; Krause, W; Speck, U; Wendt, H, 1980
)
0.52
"A pharmacokinetic investigation was carried out on a group of 13 elderly patients (2 males, 11 females, mean age 79 years) who were either mildly hypertensive or had a history of hypertension."( [Pharmacokinetics of pindolol in a group of elderly hypertensive patients (author's transl)].
Kerle, FH; Salathé, B, 1980
)
0.58
" Although there was a statistically significant difference in certain pharmacokinetic parameters (maximum plasma concentration, area under the curve, elimination constant and elimination half-life) between elderly patients (more that 60 years) and young persons (20-30 years) no significant differences were found as far as smoking and nonsmoking is concerned."( Influence of smoking and age on pharmacokinetics of beta-receptor blockers.
Beveridge, T; Fitscha, P; Hitzenberger, G; Nüesch, E; Pacha, W, 1982
)
0.26
" They differ from one another not only in their pharmacologic profiles (cardioselectivity, intrinsic sympathomimetic activity, membrane-stabilizing activity) but also in their metabolic and pharmacokinetic profiles."( Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents.
Meier, J, 1982
)
0.55
" The data suggest that in the treatment of angina on effort, beta blockers should be prescribed according to their pharmacokinetic properties to achieve adequate suppression of the heart rate during exercise."( Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics.
Cosgrove, NM; Kostis, JB; Krieger, SD; Lacy, CR, 1984
)
0.58
" The mean peak concentration was 30."( Pharmacokinetics of pindolol in Kenyan Africans.
Juma, FD, 1983
)
0.59
"6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet."( Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study.
Krause, W; Lennert, C,
)
0.45
"In a cross-over pharmacokinetic study in 8 healthy volunteers a retard formulation containing pindolol 30 mg was compared with the normal 15 mg."( Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets.
Aellig, WH; Nüesch, E; Pacha, W, 1982
)
0.77
" The pharmacokinetic parameters obtained in normal volunteers were compared with corresponding values obtained in patients with hypertension, renal insufficiency, or liver impairment."( Pharmacokinetics of pindolol in humans and several animal species.
Schwarz, HJ, 1982
)
0.59
"1 Pharmacokinetic investigations were carried out in a group of 32 ambulant normal male volunteers in order to determine the effect of age and smoking on steady-state plasma levels of pindolol and propranolol."( Effects of age and smoking on the pharmacokinetics of pindolol and propranolol.
Beveridge, T; Fitscha, P; Hitzenberger, G; Nüesch, E; Pacha, W, 1982
)
0.7
"The goal of the present work was to determine the effect of clarithromycin (CAM) administration on the pharmacokinetic properties of pindolol in rats."( Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats.
Harashima, H; Komori, T; Otagiri, M; Shimoishi, K, 1998
)
0.73
" The potential interaction between these markers was investigated in a pharmacokinetic study where markers (M) or fluconazole (F) were administered alone or together (M + F)."( Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.
Beal, JB; Gross, AS; McLachlan, AJ; Minns, I; Tett, SE, 2001
)
0.5
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Isradipine and paroxetine interact with beta-adrenoceptor/5-HT1A receptor ligands in a similar manner. Reduction in insulin sensitivity and increase in VLDL triglycerides were seen when combined with pindolol.

ExcerptReferenceRelevance
"The antihypertensive effect and safety of treatment of hypertension with isradipine, a Ca antagonist of dihydropyridine group in monotherapy and in combination with the betablocker bopindolol was assessed in a multicentre study joined by six Czechoslovak centres."( Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives.
Dvorák, I; Dzúrik, R; Fetkovská, N; Jonás, P; Kotlík, I; Markuljak, I; Petr, P; Widimský, J, 1990
)
0.72
"9% NaCl solution; vehicle) was given, alone and in combination with lidocaine (L), to groups of six pentobarbital (32."( Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol.
Beil, ME; Cabot, CF; Coram, WM; Olson, RW; Weiss, GB, 1987
)
0.47
"To evaluate the effects of isradipine alone and in combination with pindolol on glucose and lipid metabolism during long-term antihypertensive therapy."( Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Berne, C; Lind, L; Lithell, H; Pollare, T, 1994
)
0.76
" When isradipine was combined with pindolol there was also a reduction in insulin sensitivity and an increase in VLDL triglycerides, possibly as effects of the beta-adrenergic blockade."( Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Berne, C; Lind, L; Lithell, H; Pollare, T, 1994
)
0.8
"5 mg/day or placebo for nine days in combination with three consecutive TSD cycles."( Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial.
Barbini, B; Benedetti, F; Campori, E; Colombo, C; Smeraldi, E, 1999
)
0.54
" Here we determined whether the beta-adrenoceptor/5-HT1A receptor ligands (+/-)-pindolol, (-)-tertatolol and (-)-penbutolol, interact with paroxetine in a similar manner."( Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study.
Clifford, EM; Cowen, PJ; Gartside, SE; Sharp, T, 1999
)
0.78
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

The absolute oral bioavailability of pindolol has been estimated by two analytical methods. Plasma concentrations and 54-h urinary excretion (after both oral and intravenous dose) were studied in 6 healthy volunteers and 13 patients with intestinal malabsorption.

ExcerptReferenceRelevance
" The initial rate of absorption was inversely correlated with creatinine clearance."( Pharmacokinetics of intravenous and oral pindolol in hypertensive patients with chronic renal failure.
Chau, NP; Levenson, JA; Safar, ME; Simon, AC; Weiss, YA, 1978
)
0.52
" mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%."( Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia.
Bobik, A; Fagan, ET; Jennings, GL; Korner, PI, 1979
)
1.7
" The initial rate of absorption was inversely correlated with the creatinine clearance."( Pindolol availability in hypertensive patients with normal and impaired renal function.
Chau, NP; Georges, DR; Lavene, DE; Milliez, PL; Safar, ME; Weiss, YA, 1977
)
1.7
" A comparison of beta-adrenoreceptor blocking activity after oral and intravenous administration provides information on the bioavailability of these drugs."( Experiments with pindolol (Visken) in healthy volunteers.
Aellig, WH, 1977
)
0.6
" Its bioavailability after oral administration amounts to about 70%."( Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
Aellig, WH, 1986
)
0.49
" The absolute bioavailability of the active compound is about 70%."( Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
Aellig, WH; Engel, G; Grevel, J; Niederberger, W; Nüesch, E; Rosenthaler, J, 1986
)
0.48
"Nonlinear regression analysis of plasma drug concentration data with irregular or stepwise absorption profiles was studied using multi-fraction absorption models in which drugs in the gastrointestinal tract were assumed to be divided into several fractions each with its respective lag time and absorption rate constant."( Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models.
Kohno, K; Murata, K; Noda, K; Samejima, M, 1987
)
0.27
" Beta-blocking drugs differ considerably in their bioavailability because of differences in the rate and extent of metabolism in the first past through the liver after absorption from the gut."( Clinical pharmacology of adrenergic-adrenoreceptor-blocking drugs.
Jarrott, B; Louis, WJ; McNeil, JJ; Rand, MJ; Taylor, H, 1982
)
0.26
" The bioavailability of low doses was 1-2% in the rat and 40% in the dog."( Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences.
Krause, W; Kühne, G,
)
0.45
"Pindolol kinetics and bioavailability were studied after a single dose (oral 5 mg; intravenous 3 mg) in nine patients with malabsorption (two with villous atrophies, seven with short bowel syndromes) and in six healthy volunteers."( Study of the bioavailability of pindolol in malabsorption syndromes.
Aubry, JP; Cheymol, A; Cheymol, G; Evard, D; Le Quintrec, Y, 1984
)
1.99
"The absolute oral bioavailability of pindolol has been estimated by two analytical methods, fluorimetry and GLC-ECD."( Estimation of the absolute oral bioavailability of pindolol by two analytical methods.
Aubry, JP; Cheymol, A; Cheymol, G; Guerret, M; Kiechel, JR; Lavene, D, 1983
)
0.79
"The bioavailability and pharmacokinetics of 10 mg of mepindolol sulphate and of 25 mg of hydrochlorothiazide were compared in a cross-over design in five healthy volunteers after the administration of either the single drugs (Corindolan and Esidrix) or in combination (Tenesor)."( Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study.
Krause, W; Lennert, C,
)
0.69
" To investigate pindolol absorption, a drug particularly well absorbed and with low hepatic extraction, plasma concentrations and 54-h urinary excretion (after both oral and intravenous dose) were studied in 6 healthy volunteers and 13 patients with intestinal malabsorption (coeliac disease 5 cases, short bowel syndrome 8 cases) after an overnight fasting."( [Evaluation of pindolol absorption in malabsorption syndromes].
Aubry, JP; Cheymol, A; Cheymol, G; Evard, D; Le Quintrec, Y, 1983
)
0.96
" The bioavailability of the two forms was practically identical."( Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets.
Aellig, WH; Nüesch, E; Pacha, W, 1982
)
0.55
" The bioavailability interaction was investigated with drugs often coadministered with a beta blocker."( Pharmacokinetics of pindolol in humans and several animal species.
Schwarz, HJ, 1982
)
0.59
"The plasma concentrations and bioavailability of sustained-release isosorbide dinitrate and standard-release pindolol have been compared after administration of these drugs in combination and alone."( Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
Chasseaud, LF; Darragh, A; Doyle, E; Taylor, T,
)
0.58
"The relative bioavailability of metoprolol and pindolol from capsules containing the drug preadsorbed onto activated charcoal (100 mg metoprolol tartrate/120 mg charcoal and 10 mg pindolol/20 mg charcoal) was studied in two separate studies, in healthy volunteers, using randomized, crossover designs."( The bioavailability of two beta-blockers preadsorbed onto charcoal.
Neuvonen, PJ; Ojala-Karlsson, P; Roivas, L, 1994
)
0.55
"Controlled-release buccoadhesive tablets containing pindolol were prepared and evaluated in order to achieve constant plasma concentrations during the treatment of chronic hypertension and to improve the bioavailability of pindolol by the avoidance of hepatic first-pass metabolism."( Development and in vitro evaluation of a buccoadhesive pindolol tablet formulation.
Dortunç, B; Ozer, L; Uyanik, N, 1998
)
0.8
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
" We conclude that both formulations of pindolol are equivalent with regard to extent and rate of absorption as well as pharmacodynamic effect."( Bioequivalence of two oral immediate release formulations of pindolol in healthy volunteers assessed by ratio analysis.
Hannak, D; Koch, HJ; Raschka, C, 2000
)
0.82
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pindolol's potency is equivalent to that of the selective 5-HT reuptake inhibitor fluvoxamine. In an anesthetized dog model, dosing regimens which produced stable plasma concentrations of either verapamil and/or pindolOL resulted in drug effects which were closely related to the plasma levels of the individual agents. However, the optimal dosing schedule of pindlol remains controversial.

ExcerptRelevanceReference
" For this purpose dose-response relations of seven sympathomimetic amines were compared under the influence of alpha- and/or beta-adrenolytic drugs."( alpha-Adrenoceptors mediating positive inotropic effects on the ventricular myocardium: some aspects of structure-activity relationship of sympathomimetic amines.
Endoh, M; Hillen, B; Krappitz, N; Schümann, HJ, 1976
)
0.26
" Drug dosage was selected to be proportionate to beta-adrenoreceptor-blocking potency; d-propranolol dosage equalled approximately that of racemic propranolol."( The antihypertensive action of several beta-adrenoreceptor-blocking drugs.
Waal-Manning, HJ, 1976
)
0.26
" Both timolol and acebutolol had a significant hypotensive effect at 24 hours and a low incidence of side effects, suggesting that further increases in dosage might be effective and well tolerated."( Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.
Wilcox, RG, 1978
)
0.26
" Aminobenzylpropranolol inhibited catecholamine-stimulated intracellular cyclic AMP accumulation; with increasing blockade, isoproterenol dose-response curves became progressively shifted to the right but the maximal response was unaltered."( Quantitative relationship between beta-adrenergic receptor number and physiologic responses as studied with a long-lasting beta-adrenergic antagonist.
Brooker, G; Linden, J; Terasaki, WL, 1979
)
0.26
" The dose-response curves for the two agonists were parallel, but salbutamol was approximately 1/15 as potent as isoprenaline on a weight basis."( Profile of beta-adrenoceptors in femoral, superior mesenteric and renal vascular beds of dogs.
Taira, N; Yabuuchi, Y; Yamashita, S, 1977
)
0.26
" The dose-response curve for dopamine was not affected by the antagonists pimozide (10(-6) M), yohimbine (10(-5) M) pindolol (3 x 10(-8) M) and phentolamine (10(-6) M) when these agents were given separately."( No evidence for involvement of dopaminergic receptors in the positive inotropic action of dopamine on the isolated rabbit papillary muscle.
Brodde, OE; Motomura, S; Schümann, HJ, 1978
)
0.47
"0 Hz, the log dose-response curve for the positive inotropic effect of epinine was displaced to the left, whereas the maximum of the developed tension was not changed."( Studies on the mechanism of the positive inotropic action evoked by epinine on the rabbit isolated papillary muscle at different rates of beating.
Brodde, OE; Motomura, S; Schümann, HJ,
)
0.13
" The incidence of side-effects was not affected by the change in dosage or schedule."( Treatment of essential hypertension with pindolol.
Bloem, TJ; Kerkhof, JV, 1978
)
0.52
" Mean duration of treatment was 16 months (range 8--36) and mean dosage 163 mg/day."( Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system.
Henningsen, NC; Mattiasson, I, 1979
)
0.26
" Computer analysis of the records of 8989 patients who completed the 8-weeks' study period showed that treatment with the combination product, in a dosage of 1 tablet daily in 83% of the patients, resulted in excellent blood pressure control in the majority (75%) of cases, irrespective of age or previous antihypertensive treatment, and was particularly effective in those with mild to moderate hypertension who had previously not received any therapy."( A multi-centre general practice trial of a pindolol/clopamide combination ('Viskaldix') in essential hypertension.
Cameron, EG; Crowder, D, 1979
)
0.52
" The latter dosage of pindolol is above those used clinically."( Electrophysiologic effects of pindolol on atrioventricular conduction in canine heart.
Arakawa, T; Kambe, T; Sakamoto, N, 1979
)
0.86
"7 years) with severe essential hypertension (n = 21) and renovascular hypertension (n = 1) were treated with a mean daily dosage of 16."( [Minoxidil in treatment resistant hypertension].
Furrer, J; Nussberger, J; Reuteler, H; Siegenthaler, W; Studer, A; Tenschert, W; Vetter, W, 1979
)
0.26
" In twenty-two previously untreated cases given a single daily dosage of pindolol (mean 13-0 mg, range 5 mg- 30 mg), adequate blood pressure control was achieved within five weeks and maintained in the nineteen patients examined at Week 25."( Once daily administration of pindolol in the treatment of hypertension.
Blowers, AJ; Dhatariya, RC, 1977
)
0.78
"5 Hz, the dose-response curve for phenylephrine via alpha-adrenoceptors was shifted to the left (delta pD2-0."( Influence of temperature and frequency on the positive inotropic action of phenylephrine in the isolated rabbit papillary muscle.
Endoh, M; Hillen, B; Schümann, HJ, 1977
)
0.26
"15 patients (4 females, 11 males, 21 to 55-year old) with mild to moderate essential hypertension (EH) were treated with placebo for two weeks and thereafter with increasing doses of prindolol (15 to 38 mg/day in the mean) and kept on a mean maintenance dosage of 32 mg/day for an average of 16 weeks in all."( Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension.
Banthien, F; Brecht, HM; Schoeppe, W, 1976
)
0.26
" These typical dose-response relations between pindolol and contractility parameters are considered to be due to lacking cardiac depressive properties combined with significant so-called positive intrinsic activity."( [Acute myocardial infarct and pindolol. Effect of a beta sympatholytic with intrinsic sympathomimetic activity on hemodynamics and contractility].
Abendroth, RR; Hübner, H; Meesmann, W; Stephan, K, 1976
)
0.8
" The dose-response curve for phenylephrine was markedly shifted to the right by raising the temperature (pD2=0."( Influence of temperature on the positive inotropic effects mediated by alpha-and-beta-adrenoceptors in the isolated rabbit papillary muscle.
Endoh, M; Schümann, HJ; Wagner, J, 1975
)
0.25
" plasma pindolol levels were significantly lower on the twice-daily dosage regimen."( Pindolol in hypertension: twice-daily versus thrice-daily dosage.
Waal-Manning, HJ; Wood, AJ, 1975
)
2.13
" In pemphigus erythematosus, very good results were obtained in 3 of 5 cases, and failure in 2 cases was probably related to insufficient dosage of steroids, or no treatment with steroids at all."( Visken as supplementary drug in the treatment of pemphigus.
Blaszczyk, M; Chorzelski, T; Jablonska, S; Maciejowska, E, 1975
)
0.25
" Preincubation of opossum kidney cell line cell monolayers with 5-HT resulted in 5-HT1B receptor-mediated desensitization expressed as a 4-fold rightward shift of the dose-response curve and a 10 to 29% decrease of maximal inhibition of forskolin-stimulated cyclic AMP production."( Desensitization and down-regulation of the 5-hydroxytryptamine1B receptor in the opossum kidney cell line.
Bylund, DB; Pleus, RC, 1992
)
0.28
" However, the isoproterenol dose-response curves for the beta 2AR were shifted to the left, compared with those for the beta 1AR (EC50 of 52."( Beta 1- and beta 2-adrenergic receptors display subtype-selective coupling to Gs.
Green, SA; Holt, BD; Liggett, SB, 1992
)
0.28
" If normalization of diastolic blood pressure (BP) had not been reached, the dosage was increased to 5 mg."( MIS (Multicentric Isradipine Study of antihypertensive therapy).
Balazovjech, I; Dzúrik, R; Fetkovská, N; Kvasnicka, J; Lupínek, Z; Mayer, O; Pidrman, V; Widimský, J, 1992
)
0.28
" The patches showed a good local and systemic tolerability in both studies over a dosing interval of up to 7 days."( Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
Drewe, J; Gyr, K; Kissel, T; Meier, R; Munzer, J; Thumshirn, M; Timonen, U, 1991
)
0.51
" The clinical relevance of the effects was not examined, but similar changes have been reported for other beta-blockers which did not appear to be clinically relevant and did not affect the dosage required to treat hypertension."( Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.
Holmes, D; Houle, JM; Nuesch, E; Rosenthaler, J, 1991
)
0.54
" (-)-Pindolol (30 and 100 nmol/kg) shifted the dose-response curves of both drugs significantly and in a similar manner to the right."( Involvement of 5-HT1A receptors in blood pressure reduction by 8-OH-DPAT and urapidil in cats.
Beller, KD; Kolassa, N; Sanders, KH, 1990
)
0.79
" At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure."( Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991
)
0.54
" The beta-antagonist effects of the three substances were also studied, by running a dose-response curve to noradrenaline or adrenaline as appropriate following the addition of the substance of interest."( Effects of dilevalol on human atrial muscle.
Brown, MJ; Sanders, L, 1990
)
0.28
" The aim of this study was to define the optimal dosage of bopindolol in outpatients with mild to moderate hypertension and to compare it to atenolol in term of tolerance and efficacy, both administered once daily."( Dose-finding study with bopindolol in arterial hypertension.
Peter, R; Siegenthaler, H; Willimann, P, 1986
)
0.81
"The clinical efficacy of bopindolol, a new, long-acting beta-adrenoceptor blocking drug, in a dosage of 1-2 mg daily was compared with that of atenolol (50-100 mg daily) in 33 patients with mild or moderate arterial hypertension who were treated for a total period of 12 months."( Evaluation of the antihypertensive effect of a beta-blocker with the aid of daily blood pressure profiles.
Abetel, G; Genoud, G; Karly, M, 1986
)
0.57
" Within this dosage range, bopindolol itself had no significant effect on PRA."( Effect of bopindolol on renin secretion and renal excretory function in rats.
Anderson, LA; Barrett, RJ; Proakis, AG; Taylor, DR; Wright, KF, 1989
)
0.95
" Lactate reduced isoproterenol-induced lipolysis in a dose-response fashion and such inhibition became significant only at 16 mmol/l lactate."( Influence of lactate on isoproterenol-induced lipolysis and beta-adrenoceptors distribution in human fat cells.
Cardone, F; Cignarelli, M; Corso, M; De Pergola, G; Di Paolo, S; Garruti, G; Giorgino, R; Nardelli, G, 1989
)
0.28
" The dosage was increased every month up to 2 mg bopindolol and 200 mg atenolol."( Bopindolol and atenolol in patients with stable angina pectoris. Double-blind randomized comparative trial.
Hertzeanu, H; Kellermann, JJ; Loidl, AF; Shemesh, J, 1989
)
1.25
" Perfusion with adenosine for a minimum of 90 min followed by washout resulted in a 40% depression of the dose-response curve of left ventricular dP/dt to isoproterenol."( Persistent desensitization of the heart to the inotropic action of isoproterenol by adenosine.
Lee, JT; Newman, WH; Webb, JG, 1989
)
0.28
" They were submitted to clinical exam, stress testing and plasma lipids dosage before and after four weeks of treatment."( [Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension].
Bellotti, G; Braga, A; Pileggi, F; Santomauro, A; Serro-Azul, JB; Serro-Azul, LG; Wajngarten, M; Yazbek Júnior, P, 1989
)
0.28
" The inactivation of a small receptor fraction shifted the dose-response curves for isoprenaline and clonidine to the right but did not alter the maximum effect of the agonists (responsiveness)."( Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate.
Arner, P; Engfeldt, P; Hellmér, J; Ostman, J; Wennlund, A, 1988
)
0.27
" Furthermore, the hormone caused a dose-dependent maximum 10-fold shift to the right of the dose-response curve for isoprenaline-induced lipolysis without changing the amplitude of the curve."( Effects of insulin on adrenoceptor binding and the rate of catecholamine-induced lipolysis in isolated human fat cells.
Arner, P; Engfeldt, P; Hellmér, J; Wahrenberg, H, 1988
)
0.27
" However, as dosage adjustment and close observation may be necessary to minimise side effects, the use of this combination should be limited to hospital practice."( Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.
McGourty, JC; Silas, JH; Solomon, SA, 1985
)
0.27
" Dose-response curves for stimulation of both rate and force by the beta 2-selective agonists procaterol and zinterol were shifted to a much greater extent by selective blockade of beta 1-adrenoceptors with metoprolol than by selective blockade of beta 2-adrenoceptors with ICI 118,551, suggesting that these compounds caused their effects by activating beta 1-adrenoceptors."( Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart.
Abel, PW; Juberg, EN; Minneman, KP, 1985
)
0.27
" Computer-assisted analysis of dose-response curves resulting from the inhibition of the binding of [125I]iodopindolol by the beta-1 and beta-2 selective compounds ICI 89,406 and ICI 118,551 revealed that approximately one-third of the beta adrenergic receptors on these cells were beta-1 receptors."( Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists.
Barrett, DA; Molinoff, PB; Neve, KA, 1985
)
0.48
" The dose-response curves of dilevalol and labetalol were shifted to the right with propranolol pretreatment."( Intrinsic beta-sympathomimetic activity of dilevalol, R, R-isomer of labetalol.
Matsunaga, K; Nakamura, K; Ueda, M, 1985
)
0.27
"A double-blind randomized study was designed to investigate differences in the recovery of finger skin temperature after finger cooling during dosing with placebo or one of four beta-blockers: propranolol, atenolol, pindolol, and acebutolol."( The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects.
de Boo, T; Lemmens, WA; Lenders, JW; Salemans, J; Thien, T; van't Laar, A, 1986
)
0.46
" Treatment of intact vasa deferentia with increasing concentrations of BAAM resulted in a progressive rightward shift in the dose-response curve to isoprenaline or salbutamol followed by a decreased maximum response."( Binding of agonists and antagonists to beta-adrenoceptors in rat vas deferens: relationship to functional response.
Abel, PW; May, JM; Minneman, KP, 1985
)
0.27
" The maximal fall in mean arterial pressure (MAP) was seen 3 to 4 hours after oral dosing with 10 mg of pindolol (-15 +/- 3%, mean +/- SEM)."( Systemic and renal vasodilation after beta-adrenoceptor blockade with pindolol: a hemodynamic study on the onset and maintenance of its antihypertensive effect.
Man in 't Veld, AJ; Ritsema van Eck, HJ; Schalekamp, MA; van den Meiracker, AH, 1986
)
0.72
" In order to mimic the intrinsic effects of the partial agonist drugs, control dose-response curves for isoproterenol were determined in pithed rats in which the base-line heart rate was elevated by thoracic spinal cord stimulation."( Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
Cavero, I; Hicks, PE; Langer, SZ; Lefevre-Borg, F; Manoury, P, 1987
)
0.48
" Chronotoxicity of a single LD50 dosage of beta-adrenoceptor blocking agent, pindolol, was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto control rats (WKY)."( Chronotoxicity of beta-adrenoceptor blocking agent in spontaneously hypertensive rats.
Ebihara, A; Fujimura, A, 1987
)
0.5
" Increases in norepinephrine, dopamine, and epinephrine concentrations after dosing were noted, with the most marked increase in norepinephrine concentration being coincident with a significant decline in stroke volume index."( Neurohumoral profile in congestive heart failure: response to beta-blockade.
Binkley, PF; Leier, CV; Lewe, R; Lima, J; Unverferth, DV, 1988
)
0.27
"1 microM), followed by washout, produced concentration-dependent rightward shifts of the dose-response curve to cumulative additions of (-)-isoprenaline and oxymethylene-isoprenaline and reductions in the maximal response."( Persistent beta-adrenoceptor blockade with alkylating pindolol (BIM) in guinea-pig left atria and trachea.
Molenaar, P; Pitha, J; Russell, F; Summers, R, 1988
)
0.52
" Under pindolol, on the other hand, a significant impairment of sleep quality was observed after acute dosage and a decrease in feeling refreshed after sleep, continuing up to day 14 of treatment."( [Comparative study of the central nervous system effect of the beta receptor blockaders pindolol and bisoprolol].
Görtelmeyer, R; Klingmann, I, 1985
)
0.95
" Then salbutamol was administered by a dosimetric aerosol (DA) at the usual dosage (200 micrograms) and the change in FEV1 was observed at 60 min; thereafter 40 micrograms of ipratropium bromide (IB) were administered by DA and FEV1 was measured after 60 min."( Influence of pindolol on asthmatics and effect of bronchodilators.
Antoniadou, H; Georgopoulos, D; Giulekas, D; Papakosta, D; Sotiropoulou, E; Vamvalis, C, 1986
)
0.64
" At each 7 biweekly evaluations, the patient's cumulative bronchodilator dose-response to inhaled isoproterenol (0."( The effect of procaterol treatment on beta-adrenergic bronchodilation and polymorphonuclear leukocyte responsiveness.
Arbabian, M; Borgen, L; Busse, WW; Ruoho, A; Sharpe, G; Smith, A, 1985
)
0.27
"Twenty-one patients with mild or moderate hypertension were randomised to receive either Atenolol 100 mg (N = 10) or Pindolol 15 mg (N = 11) in a once daily dosage over a two month period."( [Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension].
Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Guillard, O; Herpin, D; Piriou, A, 1988
)
0.79
" +/- Pindolol, an antagonist at 5-HT1 receptors, showed a biphasic dose-response curve with a fall in entry ratio at one high dose."( Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors.
Critchley, MA; Handley, SL, 1987
)
0.79
" These results indicate that the slope of the left ventricular ESP/ESD relation is not altered following repeated dosing with pindolol in subjects with congestive heart failure."( Preservation of the end-systolic pressure/end-systolic dimension relation following pindolol in congestive heart failure.
Binkley, PF; Leier, CV; Lewe, RF; Unverferth, DV, 1988
)
0.71
" In an anesthetized dog model, dosing regimens which produced stable plasma concentrations of either verapamil and/or pindolol resulted in drug effects which were closely related to the plasma levels of the individual agents."( Hemodynamic and pharmacokinetic aspects of the interactions between verapamil and pindolol.
Hamann, SR; Kaltenborn, KE; McAllister, RG, 1987
)
0.71
" Heart rate was lowest during propranolol dosing and blood pressure was lowest during labetalol dosing irrespective of the labetalol dose used."( Chronic effects of labetalol, pindolol, and propranolol on calf blood flow in intermittent claudication.
Lepäntalo, M, 1985
)
0.56
"The plasma concentration-response relationships of oral and intravenous pindolol and propranolol have been studied in a group of eight healthy male subjects who received each dosage form in a randomized single-blind cross-over manner."( Contrasts between pindolol and propranolol concentration-response relationships.
Aellig, WH; Carruthers, SG; Pacha, WL, 1985
)
0.84
" In the adipocyte there were no significant effects of receptor site loss on the isoprenaline dose-response curve."( Irreversible antagonism of beta-adrenoceptors with para-amino-benzyl-carazolol provides further evidence for an atypical rat adipocyte beta-adrenoceptor.
Bojanic, D; Nahorski, SR, 1984
)
0.27
" One hour after oral dosing (10 mg), the drug reduced supine arterial pressure significantly."( Direct 24-hour haemodynamic monitoring after starting beta-blocker therapy: studies with pindolol in hypertension.
Man in't Veld, AJ; Schalekamp, MA; v d Meiracker, A; van Eck, HR; Wenting, GJ, 1984
)
0.49
" The dose-response curve for propranolol inhibition of 125I-hydroxybenzylpindolol binding duplicated that reported for its physiologic action."( Beta receptor occupancy. Assessment in the intact animal.
Homcy, CJ; Kopiwoda, S; Strauss, HW, 1980
)
0.49
" Exercise tests were performed after each dosing period; isoprenaline stimulation was studied at the highest dose level."( Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs.
Bodem, G; Gugler, R; Höffgen, K; Krist, R; Raczinski, H, 1980
)
0.26
" Therefore no adjustment of the usual dosage is necessary when prescribing for this age group."( [Pharmacokinetics of pindolol in a group of elderly hypertensive patients (author's transl)].
Kerle, FH; Salathé, B, 1980
)
0.58
" Thus shifts of the dose-response curves in BP and HR were observed."( A simple method to determine the ratio of cardiac to vascular beta-receptor blockade in the rat in vivo.
Kudo, Y; Sokabe, H; Zehr, JE, 1981
)
0.26
" Standardized experiments were performed using a chronically reserpinized canine preparation for the assessment of dose-response curves of changes in hemodynamics, left ventricular contractility, heart rate, AV-conduction time, and myocardial oxygen consumption especially at therapeutic doses."( Sympathomimetic and cardiodepressant effects of acebutolol, oxprenolol, pindolol, and propranolol. A comparative study on changes in hemodynamics, contractility, heart rate, and AV-conduction time at therapeutic doses.
Bender, F; Gülker, H; Heuer, H; Kristek, J, 1981
)
0.5
" A low daily dosage is possible because of the high bioavailability, the low first-pass effect, the moderate metabolism, and the potency of this drug."( Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents.
Meier, J, 1982
)
0.55
" 2 Fourteen of the sixteen patients entered were studied on no therapy and following a minimum of 6 weeks at a constant dosage of Viskaldix."( The effect of once daily beta-adrenoceptor blocker-thiazide diuretic combination on the ambulatory blood pressure.
Gould, BA; Hornung, RS; Kieso, H; Mann, S; Raftery, EB, 1982
)
0.26
" It is concluded that the acetylator phenotype does not affect the therapeutic efficacy or dosage requirement of endralazine."( Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
Bogers, WA; Holmes, DG; Huunan-Seppala, A; Wideroe, B; Wideroe, TE, 1983
)
0.27
" In patients who respond to modest doses of pindolol, twice or even once daily dosing is often adequate."( Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.
Golightly, LK,
)
1.84
" These differences account for many of the observed variations in drug action and dosage scheduling as well as for some of the side effects."( Beta-adrenergic blockers. Choosing among them.
McGoon, MD; Vlietstra, RE, 1984
)
0.27
" During a one-year treatment period following the comparative trial, the seven patients who had received bopindolol showed no evidence of tachyphylaxia, the blood-pressure remaining well controlled while the dosage was slightly reduced."( Bopindolol, a new long-acting beta-adrenoceptor antagonist--a randomized comparison against propranolol in hypertensive patients.
Axthelm, T; Kirch, W, 1983
)
1.2
" In Study 1 the short-term dose-response effects of propranolol (1-8 mg) or pindolol (0."( Is the intrinsic sympathomimetic activity (ISA) of beta-blocking compounds relevant in acute myocardial infarction?
Ahuja, RC; Hafizullah, M; Hussain, M; Nelson, GI; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1984
)
0.5
" In both preparations only the combined application of phentolamine (10(-6) M) and pindolol (3 X 10(-8) M) shifted the entire dose-response curves for the positive inotropic effect of dopamine to the right, while either antagonist used separately had no effect."( The mode of direct action of dopamine on the rabbit heart.
Brodde, OE; Inui, J; Motomura, S; Schümann, HJ,
)
0.36
"Pindolol was given once a day to 15 patients with mild to moderate hypertension to investigate whether once-daily dosage controls blood pressure for 24 h and whether a paradoxical rise in blood pressure occurs with increasing dosage."( Positive relationship between the dosage of pindolol and its antihypertensive effect.
Andrén, L; Hansson, L,
)
1.84
" Blood pressure control remained good during this time, and the dosage was slightly reduced."( Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
Axthelm, T; Kirch, W,
)
0.13
" Unexpected differences, not previously reportd, were found in the shapes of the cAMP accumulation dose-response curves of norepinephrine and isoproterenol."( Neonatal rat pinealocytes: typical and atypical characteristics of [125I]iodohydroxybenzylpindolol binding and adenosine 3',5'-monophosphate accumulation.
Auerbach, DA; Aurbach, GD; Klein, DC; Woodard, C, 1981
)
0.48
" Plasma concentrations (measured fluorometrically), isoproterenol dose-response relationship (to calculate the dose needed to increase heart rate by 25 bpm), renin, epinephrine, and norepinephrine were measured several times before and after the first and last dose."( Constant kinetics and constant concentration-effect relationship during long-term beta-blockade with pindolol.
Galeazzi, RL; Pirovino, M; Weidmann, P, 1983
)
0.48
"To test the hypothesis that the depression of cardiac performance induced by competitive blockade of sympathetic stimulation at beta-adrenoceptors could be attenuated by the addition of a high level of intrinsic sympathomimetic activity (ISA) or concomitant alpha- and beta-blockade, the haemodynamic dose-response effects of propranolol (non-cardioselective, no ISA), pindolol (non-cardioselective, high ISA) and labetalol (non-cardioselective, alpha-blocker) were compared in a randomized study of 30 patients with stable coronary artery disease."( Beta-blockade in ischaemic heart disease--influence of concomitant ISA or alpha-blockade on haemodynamic profile.
Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH, 1983
)
0.43
" It is concluded that indapamide and pindolol at the dosage levels used are drugs of comparable antihypertensive activity."( Indapamide versus beta-blocker therapy: a double-blind, crossover study in essential hypertension.
Jurisic, M; Rumboldt, M; Rumboldt, Z, 1984
)
0.54
" The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing."( [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
Delise, P; Di Pede, F; Piccolo, E; Raviele, A, 1984
)
0.27
"To determine whether the depression of left ventricular pumping activity associated with beta-blockade alone could be offset by a substantial degree of partial agonist activity, the haemodynamic dose-response effects of intravenous propranolol and pindolol were compared in a randomised between-group saline controlled study in twenty patients with angiographically proven coronary artery disease."( Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease.
Ahuja, RC; Nelson, GI; Okoli, RC; Silke, B; Taylor, SH, 1983
)
0.68
" The dosage of each drug was adjusted at monthly clinic visits until satisfactory control of blood pressure was achieved (140/90 mm Hg or less by cuff) or the maximum dose in the study protocol was reached."( Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
Floras, JS; Hassan, MO; Jones, JV; Sleight, P, 1982
)
0.48
" The dose-response curves for isoprenaline competition in binding of [125I]iodohydroxybenzylpindolol by dividing cells showed that the EC50 (effective concentration for half maximum activity) value for isoprenaline was higher in the presence of p[NH]ppG."( Characteristics of the beta-adrenergic adenylate cyclase system of developing rabbit bone-marrow erythroblasts.
Arnstein, HR; Setchenska, MS, 1983
)
0.49
" It is concluded that the differences between endralazine and hydralazine in dosage and metabolism may explain the lower immunogenic activity of endralazine."( Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.
Bogers, WA; Meems, L, 1983
)
0.27
" We can look forward to newer agents that are efficacious as monotherapy and on a daily or twice daily dosage regimen for the treatment of the vast majority of hypertensive patients."( Newer antihypertensive agents.
Thind, GS, 1980
)
0.26
" The daily dosage of guanfacine did not have to be changed during the 3 years of treatment."( Blood pressure and prolactin: effects of guanfacine. Three-year follow-up study.
Gerber, S; Hauger-Klevene, JH; Pinkas, MB,
)
0.13
"Seventeen patients with mild to moderate essential hypertension received during three consecutive 4 wk periods a matched placebo, the thiazide-like diuretic, clopamide in a low dosage of 5 mg/day, or this diuretic combined with the betablocker, pindolol in a low dosage of 10 mg/day."( Reversal of diuretic-induced increases in serum low-density-lipoprotein cholesterol by the betablocker pindolol.
Bachmann, C; Mordasini, R; Riesen, W; Schiffl, H; Weidmann, P, 1982
)
0.66
" Pindolol and propranolol lowered PRA comparably at equivalent dosages, although this effect was not consistently observed in all studies or at all dosage levels."( Pindolol: effects on blood pressure and plasma renin activity.
Bennett, CM; Glassock, RJ; Gonasun, L; Hamilton, B; Kirkendall, W; Maxwell, M; Weitzman, RE; Winer, N, 1982
)
2.62
" These data show that abrupt withdrawal of pindolol after long-term dosing leads to transient cardiac hyperresponsiveness of resting and exercise heart rate at the same time as persistent cardiac hyporesponsiveness to isoproterenol."( Cardiac hyper- and hyporesponsiveness after pindolol withdrawal.
Langlois, S; Rangno, RE; Stewart, J, 1982
)
0.79
" The bioavailability of the tablet dosage forM proposed for marketing was compared to that of a solution and found to be optimal."( Pharmacokinetics of pindolol in humans and several animal species.
Schwarz, HJ, 1982
)
0.59
"Administration of a once-daily dosage of pindolol seems to be a simple and effective way to treat mild to moderate hypertension and one that produces relatively few side effects."( Once-a-day treatment of hypertension with pindolol.
Frithz, G, 1982
)
0.79
"Ambulatory monitoring of intra-arterial blood pressure was used to assess patterns of circadian blood pressure in 12 hypertensive patients who were treated with pindolol in either a once- or twice-daily dosage regimen."( Once-daily pindolol in hypertension: an ambulatory assessment.
BalaSubramanian, V; Craig, MW; Mann, S; Raftery, EB, 1982
)
0.85
"Effects of intravenous and long-term oral dosing with pindolol on renal function were examined in eight hypertensive patients with reduced renal function."( Effects of pindolol on renal function II. Effects on intravenous and prolonged oral dosing.
Boner, G; Rosenfeld, JB; Wainer, E, 1982
)
0.9
" Acutely dosed and chronically treated rhesus monkeys showed the same metabolic pattern in urine."( Pindolol: disposition and metabolism in rhesus monkeys after chronic treatment.
Donatsch, P; Galliker, H; Kiechel, JR; Maurer, G; Meier, J, 1981
)
1.71
" The flatter dose-response curve of pindolol for exercise heart rate (EHR) has been reported from practolol and oxprenolol, which also exert partial agonist activity."( Measurement of partial agonist activity of pindolol.
Carruthers, SG; Twum-Barima, Y, 1981
)
0.8
" Dose-response curves for heart rate, cardiac output, arterial blood pressure and pulmonary artery pressure were obtained in 16 male patients after intravenous administration of three increasing doses of pindolol, propranolol or placebo."( A comparison of the acute haemodynamic effects of propranolol and pindolol at rest and during supine exercise in man.
Carlsen, JE; Hartling, O; McNair, A; Svendsen, TL; Trap-Jensen, J, 1980
)
0.69
"01-1 mg/kg) induced penile erection in rats with bell-shaped dose-response curves."( Role of the dopaminergic, serotonergic and cholinergic link in the expression of penile erection in rats.
Maeda, N; Matsuoka, N; Yamaguchi, I, 1994
)
0.29
" If, after 4 weeks of treatment, CR-determined diastolic blood pressure (DBP) was still > 90 mm Hg, this dosage was doubled (n = 327) and, at week 8, pindolol at 5 mg or spirapril at 3 mg daily was added if necessary for blood pressure control."( A multicenter study using causal readings, self-recordings, and ambulatory blood pressure monitoring to assess isradipine effects. AMICUS Study Group.
Fitscha, P; Magometschnigg, D; Meisner, W, 1994
)
0.49
" EEDQ treatment shifted the dose-response curve for 5-HT to the right by 6-7-fold, accompanied by a reduction (30-50%) in maximal response."( Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.
Adham, N; Branchek, T; Ellerbrock, B; Hartig, P; Weinshank, RL, 1993
)
0.29
" This increase in agonist affinity might, therefore, minimize the shift to the right seen in the dose-response curve to noradrenaline during acidosis."( The effect of acidosis on beta-adrenergic receptors in ferret cardiac muscle.
Nimmo, AJ; Orchard, CH; Than, N; Whitaker, EM, 1993
)
0.29
" However, since the dose-response curves for quipazine during the day and night are virtually identical, we hypothesize that the nighttime 5-HT receptor is a 5-HT1-like receptor."( Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
Dean, RR; Edgar, DM; Heller, HC; Miller, JD; Prosser, RA, 1993
)
0.29
" In patients showing a decrease of the potassium plasma level, potassium sparing diuretic-amiloride should be added or the dosage of the drug should be halved."( [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)].
Balazovjech, I; Havlík, V; Havránek, P; Hulínský, V; Kroupa, E; Lánská, V; Nikodýmová, L; Pátek, F; Svihovcová, P; Svítil, F; Widimský, J, 1996
)
0.54
" Each antagonist alone caused smaller shifts to the right in the dose-response curve to NE and, when present simultaneously, completely abolished the NE response."( Inducible expression of beta 1- and beta 2-adrenergic receptors in rat C6 glioma cells: functional interactions between closely related subtypes.
Esbenshade, TA; Guerrero, SW; Minneman, KP; Zhong, H, 1996
)
0.29
"We generated dose-response data for the endogenous and ultra-short-acting hallucinogen, N,N-dimethyltryptamine (DMT), in a cohort of experienced hallucinogen users, measuring multiple biological and psychological outcome measures."( Human psychopharmacology of N,N-dimethyltryptamine.
Strassman, RJ, 1996
)
0.29
"003 mumol kg-1 shifted to the right the dose-response curve of prenalterol for its positive chronotropic effect."( Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors.
Malinowska, B; Schlicker, E, 1996
)
0.53
" For serotonin-induced phospholipase C stimulation, reductions in receptor number result in dose-response curves that shift downward and rightward, reflecting both a decreasing maximal effect as well as an increasing ED50."( The human 5-hydroxytryptamine 1A receptor differentially modulates phospholipase C and adenylyl cyclase activities.
Beliveau, M; Fargin, A; Fenrick, R; Pou, C, 1996
)
0.29
" The aim of the present study was to examine whether pindolol may increase the efficacy of a subtherapeutical dosage of trazodone in the treatment of major depression and TRD, defined according to the Thase and Rush criteria (1995)."( Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
Desnyder, R; Maes, M; Vandoolaeghe, E, 1996
)
0.79
" The dose-response and time-course effects on the secretion of oxytocin and vasopressin revealed that alnespirone stimulated oxytocin in a dose-dependent manner, but did not increase vasopressin secretion."( A comparison of the oxytocin and vasopressin responses to the 5-HT1A agonist and potential anxiolytic drug alnespirone (S-20499).
Brownfield, MS; Levy, AD; Li, Q; Van de Kar, LD, 1998
)
0.3
" In patients who have experienced only partial treatment results, the clinician should first consider optimizing antidepressant dosage or lengthening therapy."( Practical management of treatment-resistant depression.
Cadieux, RJ, 1998
)
0.3
" Dose-response studies showed that the potency of cyanopindolol to inhibit clearance of 5-HT was equivalent to that of the selective 5-HT reuptake inhibitor fluvoxamine."( 5-HT(1B) receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo.
Daws, LC; Frazer, A; Gerhardt, GA; Gould, GG; Teicher, SD, 2000
)
0.55
" It is also suggested that positron emission tomography may be used to define therapeutic dosing early on in the process of clinical evaluation of new treatment strategies."( Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Broft, A; Laruelle, M; Martinez, D, 2000
)
1.75
" However, the optimal dosing schedule of pindolol remains controversial."( A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.
Dauphin, A; Gruwez, B; Tod, M, 2005
)
0.81
" Serial bleeding of mice is advantageous for the reduction of animal usage, dosing errors, and animal-to-animal variation."( Supercritical fluid chromatography-tandem mass spectrometry for the enantioselective determination of propranolol and pindolol in mouse blood by serial sampling.
Chen, J; Cook, J; Hsieh, Y; Korfmacher, WA; Morrison, R, 2006
)
0.54
" The patient took 20 mg daily for five days and then decided, on her own, to decrease the dosage after experiencing insomnia, a common adverse effect of duloxetine."( Facial flushing associated with duloxetine use.
Ezzo, DC; Patel, PN, 2007
)
0.34
"Patients with major depression were randomized to either active or placebo pindolol 20 mg retard daily dosage and concomitantly treated with venlafaxine for 19 days."( A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
Bech, P; Lunde, M; Martiny, K; Plenge, P, 2012
)
0.83
"Given that drug dosing schedules utilise eGFR values as the basis for modifying drug dosing, our results would suggest that a recommendation of a dose reduction according to eGFR alone should be treated with caution."( GFR may not accurately predict aspects of proximal tubule drug handling.
Duffull, SB; Putt, TL; Schollum, JB; Walker, RJ, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
antiglaucoma drugAny drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
indolesAny compound containing an indole skeleton.
secondary amineA compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Pindolol Action Pathway478

Protein Targets (72)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency14.12540.707912.432431.6228AID1708
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency2.46390.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
NFKB1 protein, partialHomo sapiens (human)Potency5.01190.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.88320.000714.592883.7951AID1259392
regulator of G-protein signaling 4Homo sapiens (human)Potency8.43680.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.23020.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency5.01190.28189.721235.4813AID2326
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
ParkinHomo sapiens (human)Potency16.36010.819914.830644.6684AID720573
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency2.98470.023723.228263.5986AID743222
alpha-galactosidaseHomo sapiens (human)Potency10.00004.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency20.81140.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency29.84930.000723.06741,258.9301AID743085; AID743122
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency25.11890.316212.443531.6228AID902
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency0.02380.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.10000.039816.784239.8107AID995
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.31620.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency25.11890.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.03160.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency3.21770.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.15100.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00050.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.00040.00000.66359.5499AID301363; AID625205
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00090.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.00050.00011.33919.9840AID301362; AID625204
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.05940.00010.532610.0000AID254286; AID301352; AID301353; AID3840
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki114.75000.00020.667710.0000AID5270; AID5273
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.08800.00233.24158.0600AID625206
Beta-3 adrenergic receptorHomo sapiens (human)Ki0.06600.00302.30986.0450AID625206
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki114.75000.00010.601710.0000AID5270; AID5273
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.04800.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.04960.00010.739610.0000AID3695; AID4411; AID625190
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki6.30000.00010.54859.2100AID4253
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki54.00000.00010.954910.0000AID4747
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.04800.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.06900.00031.29679.2440AID3695; AID4699; AID625190
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki0.10000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki0.10000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki114.75000.00020.590910.0000AID5270; AID5273
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki7.00000.00000.705610.0000AID187171
Angiotensin-converting enzymeRattus norvegicus (Norway rat)Ki0.02400.00011.96427.3000AID3840
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Kd0.00060.00000.62888.9130AID620387; AID620391
Beta-1 adrenergic receptorHomo sapiens (human)Kd3.33500.00010.803910.0000AID620386; AID620389; AID620390
5-hydroxytryptamine receptor 1AHomo sapiens (human)EC50 (µMol)0.02700.00010.25718.0000AID3517
5-hydroxytryptamine receptor 1AHomo sapiens (human)Kd0.06310.00010.95285.0119AID438555
Beta-3 adrenergic receptorHomo sapiens (human)Kd0.58300.00010.76318.9130AID620388; AID620392
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.02700.02700.87933.0000AID3517
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.02700.02700.97093.0000AID3517
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.02700.02700.97093.0000AID3517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Activity9.70000.71005.30179.7000AID681117
Alpha-2A adrenergic receptorHomo sapiens (human)Kapp0.09300.01700.03700.0930AID1123537
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)Kapp0.09300.01700.03700.0930AID1123537
Alpha-2B adrenergic receptorHomo sapiens (human)Kapp0.09300.01700.03700.0930AID1123537
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)Kapp0.01400.00770.01190.0150AID1123536
Alpha-2C adrenergic receptorHomo sapiens (human)Kapp0.09300.01700.03700.0930AID1123537
Alpha-1D adrenergic receptorHomo sapiens (human)Kapp0.09300.01700.03700.0930AID1123537
Alpha-1A adrenergic receptorHomo sapiens (human)Kapp0.09300.01700.03700.0930AID1123537
Alpha-1B adrenergic receptorHomo sapiens (human)Kapp0.09300.01700.03700.0930AID1123537
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (221)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (282)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID416891Therapeutic index, ratio of LD50 for Wistar rat to antiarrhythmic ED50 for Wistar rat2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.
AID5270Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID620395Partial agonist activity at human beta-3 adrenergic receptor expressed in CHOK1 cells assessed as CRE-SPAP production at 1 uM by fluorescence correlation spectroscopic analysis relative to 10 uM isoprenaline2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID620387Displacement of [3H]-CGP 12177 from human beta-2 adrenergic receptor expressed in CHOK1 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID620391Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID41602Hill coefficient value assayed against rat beta adrenergic receptor1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID4699Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID566939Reduction of 8-OH-DPAT-induced hypothermia in Swiss albino mouse at 0.1 mg/kg, ip administered 45 mins prior 8-OH-DPAT challenge measured after 15 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID350216Dissociation constant, pKa of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID312895Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID41488Selectivity for beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID301353Antagonist activity at human 5HT1A expressed in mouse LM(tK-) cells assessed as inhibition of 5-HT-stimulated [35S]GTP-gamma-S binding2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID620389Antagonist activity at human beta-1 adrenergic receptor site 1 expressed in cimeterol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID41750In vitro for binding affinity against beta adrenergic receptor in rat cerebellum1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols.
AID566933Effect on hypothermia in Swiss albino mouse assessed as change in rectal body temperature at 5 mg/kg, ip dosed 15 mins after 0.1 mg/kg, sc WAY 100635 challenge measured after 60 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID301352Displacement of [3H]DPAT from human 5HT1A receptor2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID171589Intrinsic sympathomimetic action in reserpinized rats1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID566930Effect on hypothermia in Swiss albino mouse assessed as change in rectal body temperature at 5 mg/kg, ip dosed 15 mins after 0.1 mg/kg, sc WAY 100635 challenge measured after 30 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID3885Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT(1A) and 5-HT re-uptake ligands.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID620388Displacement of [3H]-CGP 12177 from human beta-3 adrenergic receptor expressed in CHOK1 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID40537Selectivity for beta-1 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID1576360Permeability coefficient of compound in phosphate buffer containing 0.5% DMSO at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID620392Antagonist activity at human beta-3 adrenergic receptor expressed in fenoterol-stimulated CHOK1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID608394Permeability of the compound at 100 uM after 5 hrs by PAMPA2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566942Reduction of 8-OH-DPAT-induced hypothermia in Swiss albino mouse at 0.1 mg/kg, ip administered 45 mins prior 8-OH-DPAT challenge measured after 60 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID41889Tested for intrinsic sympathomimetic activity (ISA); Antagonist with partial agonistic properties1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID4096Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1332041Intrinsic activity at human 5-HT1A expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 20 mins liquid scintillation counting method relative to serotonin2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID4253Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
2-(1-Naphthyloxy)ethylamines with enhanced affinity for human 5-HT1D beta (h5-HT1B) serotonin receptors.
AID566926Effect on hypothermia in Swiss albino mouse assessed as change in rectal body temperature at 0.1 mg/kg, ip after 60 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID1576348Permeability coefficient of compound in phosphate buffer containing 5% DMSO at pH 7.4 incubated for 7 hrs by HDC/NOPE PAMPA based spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID566927Effect on hypothermia in Swiss albino mouse assessed as change in rectal body temperature at 0.1 mg/kg, ip after 90 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID25572Dissociation constant of the compound1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1123537Displacement of [3H]DHA from beta2 adrenergic receptor in rat lung muscle by competitive binding assay1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.
AID29845Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID604740Binding affinity to human serum albumin by equilibrium dialysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID26525Distribution coefficient measured in Octanol/buffer (0.15 M KCl)1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID350218Octanol-water partition coefficient, log PC of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID350219Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1169140Retention time of the compound by EPSA supercritical fluid chromatography2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID566925Effect on hypothermia in Swiss albino mouse assessed as change in rectal body temperature at 0.1 mg/kg, ip after 30 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID312896Partition coefficient, log P by UPLC method2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
AID620386Displacement of [3H]-CGP 12177 from human beta-1 adrenergic receptor expressed in CHOK1 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1123538Cardio selectivity ratio of Kapp for beta2 adrenergic receptor in rat lung muscle to Kapp for beta1 adrenergic receptor in rat ventricular muscle1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.
AID5240Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID156204Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID438555Binding affinity to 5HT1A receptor2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Physical binding pocket induction for affinity prediction.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID620394Partial agonist activity at human beta-2 adrenergic receptor expressed in CHOK1 cells assessed as CRE-SPAP production at 1 uM by fluorescence correlation spectroscopic analysis relative to 10 uM isoprenaline2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID156202Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID566928Effect on hypothermia in Swiss albino mouse assessed as change in rectal body temperature at 0.1 mg/kg, ip after 120 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID21277Permeability through isolated albino rabbit cornea1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID193105Beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 1.25 mg/kg1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID620393Partial agonist activity at human beta-1 adrenergic receptor expressed in CHOK1 cells assessed as CRE-SPAP production at 1 uM by fluorescence correlation spectroscopic analysis relative to 10 uM isoprenaline2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID588966Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID194405Vasodilator activity in ganglion blocked rats. Values denote percent change in mean arterial blood pressure 30 minutes after dosing rats at 3 mg/kg intravenously1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID301362Binding affinity at human adrenergic beta-1 receptor2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID350217Octanol-water partition coefficient, log P of the cationic form of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID4747Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID3840Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT(1A) and 5-HT re-uptake ligands.
AID416888Antiarrhythmic activity against adrenaline-induced arrhythmia in iv dosed anaesthetized Wistar rat assessed as inhibition of premature ventricular beats pretreated 60 mins prior to adrenaline challenge2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.
AID254286Inhibition constant against 5-hydroxytryptamine 1A receptor2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID41751In vitro for binding affinity against beta adrenergic receptor in rat cortex1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID170571The compound was tested for antihypertensive activity in spontaneously hypertensive rats after peroral administration, dosed at 30 mg/kg1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID169089Effective dose was evaluated following intravenous administration in reserpinized normotensive anesthetized rats1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID21271Mean apparent permeability through fuzzy rat skin1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID350220Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID5273Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1123536Displacement of [3H]DHA from beta1 adrenergic receptor in rat ventricular muscle by competitive binding assay1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID48369Intrinsic Sympathomimetic Activity(ISA) determined from the ratio of the maximal compound and isoprenaline induced tachycardia in anesthetized ganglion blocked cats following intravenous administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID301363Binding affinity at human adrenergic beta2 receptor2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID566940Reduction of 8-OH-DPAT-induced hypothermia in Swiss albino mouse at 0.1 mg/kg, ip administered 45 mins prior 8-OH-DPAT challenge measured after 30 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID620390Antagonist activity at human beta-1 adrenergic receptor site 1 expressed in CGP 12177-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID416890Acute toxicity in iv dosed anaesthetized Wistar rat2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID3517Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT(1A) and 5-HT re-uptake ligands.
AID301354Antagonist activity at human 5HT1A expressed in mouse LM(tK-) cells assessed as maximal inhibition of 5-HT-stimulated [35S]GTPgammaS binding2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID4411Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID16351Percent diffusion through fuzzy rat skin after 48 h of incubation1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID26041Distribution coefficient value of the compound1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols.
AID566941Reduction of 8-OH-DPAT-induced hypothermia in Swiss albino mouse at 0.1 mg/kg, ip administered 45 mins prior 8-OH-DPAT challenge measured after 45 mins by inducible hypothermia test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID187171Displacement of specific [3H]- citalopram binding to 5-HT uptake site in rat whole cortex1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT(1A) and 5-HT re-uptake ligands.
AID21254Mono layer permeability of human intestinal Caco-2 cells1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID624215Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A1998Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 357, Issue:3
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 357, Issue:3
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID624223Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,502)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902185 (62.39)18.7374
1990's947 (27.04)18.2507
2000's255 (7.28)29.6817
2010's95 (2.71)24.3611
2020's20 (0.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.61 (24.57)
Research Supply Index8.39 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index110.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials662 (17.81%)5.53%
Reviews134 (3.60%)6.00%
Case Studies85 (2.29%)4.05%
Observational0 (0.00%)0.25%
Other2,837 (76.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Antidepressant Effect of Escitalopram: Delay of Onset. Clinical Randomized Double-blinded Study With Three Parallel Treatment Groups (Escitalopram 20mg vs Escitalopram 30mg vs Escitalopram 20 mg + Pindolol 15 mg/Day [NCT01219686]Phase 2/Phase 318 participants (Actual)Interventional2010-10-31Terminated(stopped due to Recruitment difficulties)
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04767061]Phase 49 participants (Actual)Interventional2021-04-01Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder [NCT00931775]Phase 230 participants (Actual)Interventional2002-12-31Completed
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) [NCT00895804]Phase 116 participants (Actual)Interventional2001-06-30Completed
Examination of the Pharmacokinetic Properties of Three Generic Medications and Their Respective Brand Preparations in Healthy Male Volunteers [NCT01400165]Phase 130 participants (Anticipated)Interventional2011-07-31Recruiting
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04757584]Phase 49 participants (Actual)Interventional2021-04-01Completed
A Short Term Double Blind Randomised Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression [NCT00159146]31 participants (Actual)Interventional2002-08-31Terminated(stopped due to lack of participants fulfilling inclusion criteria)
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]10 participants (Actual)Interventional2007-01-31Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors [NCT01778686]24 participants (Actual)Interventional2013-01-31Completed
Can Additional Drug Therapy Accelerate Response Time to Antidepressants: A Double-blind, Placebo-controlled Randomization Research Study for Major Depression [NCT00221494]Phase 40 participants (Actual)Interventional2004-01-31Withdrawn(stopped due to PI move)
The Mechanism of Human Non-Shivering Thermogenesis and Basal Metabolic Rate [NCT01950520]Phase 2134 participants (Anticipated)Interventional2014-02-07Recruiting
Two Part Study to Assess Comparative Bioavailability, Pharmacokinetics of a Single Dose of ACM-001.1, Two Single Doses of Pindolol (Part1) Followed by Evaluation of Steady State Pharmacokinetics, Pharmacodynamics of ACM-001.1 in HV (Part2) [NCT06028321]Phase 151 participants (Actual)Interventional2021-11-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT04767061 (10) [back to overview]Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)
NCT04767061 (10) [back to overview]Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
NCT04767061 (10) [back to overview]Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)
NCT04767061 (10) [back to overview]Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)
NCT04767061 (10) [back to overview]Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device
NCT04767061 (10) [back to overview]Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)

"Cardiopulmonary exercise testing (CPET) measures breath-by-breath oxygen production during symptom-limited exercise on a stationary bike. This permits the calculation of peak oxygen consumption (VO2). Percent predicted peak VO2 for body weight will also be calculated. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 6-weeks. This outcome was measured at the end of the first and second visit.

Interventionml/kg/min (Mean)
ON Beta Blockers10.0
OFF Beta Blockers11.4

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The balance test portion of the SPPB assesses the subject's ability to stand unassisted without the use of a cane or walker. Balance test scores range from 0 - 4 with higher scores indicating better ability to stand unassisted. Our research team conducted the balance test according to SPPB standards. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers3.9
OFF Beta Blockers3.6

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The chair rise portion of the SPPB assesses core strength. When comparing the number of seconds it takes to complete 5 chair rises, quicker speeds indicate better core strength. Our research team has chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers16
OFF Beta Blockers15.1

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The gait speed portion of the SPPB assesses the subject's lower extremity function. When comparing the number of seconds it takes to complete the 4-meter gait speed test, quicker speeds indicate better lower extremity function. Our research team conducted the 4-meter gait speed test according to SPPB standards, but have chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers4.3
OFF Beta Blockers4.6

[back to top]

Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)

"Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a) is a survey of patient-perceived cognitive deficits. Questions are ranked on a 5-point Likert scale, with higher scores indicating better cognitive function. Scores are mapped so the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse cognitive function compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3-6 weeks. The outcome measure data is the mean of the data collected during the span of the measured time points." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers53.8
OFF Beta Blockers52.4

[back to top]

Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

"The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. Questions are ranked on 5- to 7-point Likert scales, with higher scores indicating better health status. KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The max amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, bi-weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers58.7
OFF Beta Blockers66.0

[back to top]

Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)

"The EuroQol-5D Visual Analogue System (EQ-5D VAS) indicates patient-perceived health on a vertical visual analogue scale. The scale ranges from 0, indicating poorest health, to 100, indicating the best health. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers68.9
OFF Beta Blockers67.8

[back to top]

Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

"Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function) measures self-reported sexual function and satisfaction. Questions are ranked on a 6-point Likert scale, with higher scores indicating poorer sexual function and satisfaction. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame. The score ranges from 0-10 with higher scores meaning worsened sexual function." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers1.8
OFF Beta Blockers2.1

[back to top]

Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device

"The wearable activity monitoring device measures daily step count. Due to the nature of N-of-1 trials, the duration of a subject's periods varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 and 6 weeks. We will compare average step counts over 2-week periods, which will be the final 2 weeks of each period when subjects are either on their home (ON Beta Blockers) or minimally tolerated (OFF Beta Blockers) dose. The outcome measure data is the mean collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 8-weeks (last 2 weeks of each period for up to 4 periods).

InterventionCount of Steps (Mean)
ON Beta Blockers2790.5
OFF Beta Blockers3167.3

[back to top]

Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

"The PROMIS-29 assesses 7 domains with 4 questions with an additional pain intensity numeric rating scale. The patients' answers to the PROMIS-29 are scored from 1-5 (except for the pain numeric rating scale). The sum of the PROMIS-29 is the raw score transformed into a final T-score metric. Scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the PROMIS-29 raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse health compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker before enrollment, therefore, each subject's respective period for the OFF and ON periods could range between 3 - 6 weeks. The values measured over the time points were averaged." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

,
Interventionscore on a scale (Mean)
Physical Health ComponentMental Health Component
OFF Beta Blockers40.047.9
ON Beta Blockers39.846.8

[back to top]